Rare-cell analysis platform pursues neurodegeneration answers


Each region on the nanowire chip captures cells expressing the corresponding surface markers against the attached antibodies. Image designed by Jonathan Chen

A technique for spotting the small numbers of immune cells that cross the blood–brain barrier into the cerebral spinal fluid (CSF) may offer early clues on neurodegenerative disease progression.

As life expectancy rises across the world, the number of elderly people at risk of developing neurodegenerative disorders such as Alzheimer’s disease (AD) is growing. Current models of AD presume that neurodegenerative changes in the brain start well before the clinical symptoms become apparent. Accordingly it is essential to develop early detection methods to improve patient care and aid in the selection of the best treatment.

Recent research has highlighted the role of leukocyte (white blood cell) transport in the development of neurodegenerative disorders. ‘These diseases involve persistent inflammatory conditions in which leukocytes move into and out of the disease lesion and participate in disease development,’ says lead researcher Rong Fan at Yale University in the US. ‘It turns out these cells migrate into the CSF, which is like the blood of our central nervous system. Therefore, we hope to characterise these leukocytes to detect pathophysiological changes in the brain.’

However, the abundance of trafficking leukocytes in CSF is very low, meaning that large quantities of CSF are required for analysis by conventional techniques such as flow cytometry. This is both impractical in a clinical setting and very invasive for a patient. Now, Fan and co-workers have created a silicon nanowire chip coated with different leukocyte-specific antibodies to capture and separate a range of immune cell types before they are counted using laser scanning cytometry.

Only 50μL of CSF is required per assay because the nanowire platform captures cells with very high efficiency. ‘This is particularly important as CSF is collected in small volumes and is usually intended for multiple clinical diagnoses,’ says Bianxiao Cui, a nanobiotechnology expert at Stanford University, US, who was not involved in the work.

In a preliminary investigation on a small number of AD patients the team found marked differences in the levels of certain leukocyte types compared to normal CSF samples. They are now looking to collaborate with neurologists and neuropathologists to carry out a large scale clinical study to validate their results.

References

This paper is free to access until 9 May 2014. Download it here:

M Kwak et al, Nanoscale, 2014, DOI: 10.1039/c3nr06465d


Related Content

Renewed focus on dementia checked by drug challenges

3 July 2014 News and Analysis

news image

'Ticking time bomb' of global neurodegenerative disease burden will be difficult to defuse

Fast test classifies meningitis bacteria

20 January 2014 Research

news image

New technique reliably distinguishes bacterial species for tailored antibiotic treatment

Most Read

Breakup reaction hints at handedness of nature

25 September 2014 Research

news image

Dissociation of 3-bromocamphor provides clues on why nature favours one mirror image of a molecule over another

Perovskite solar cells show hydrogen production promise

26 September 2014 Research

news image

Highly efficient solar cells and catalysts made from cheap, common materials use sunlight to split water

Most Commented

Viruses melt ‘glassy’ DNA

1 October 2014 Research

news image

Researchers have shown how viruses liquefy their own DNA ready to inject into host cells

Perovskite solar cells show hydrogen production promise

26 September 2014 Research

news image

Highly efficient solar cells and catalysts made from cheap, common materials use sunlight to split water